Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OTIV
2576
DELISTED
OTI On Track Innovations Ltd
OTIV
| $940K | ﹤0.01% |
717,290
-102,010
| -12% | -$144K |
|
2577
AdvanSix
ASIX
$427M
| $937K | ﹤0.01% |
+30,000
| New | +$854K |
|
|
VSI
2578
DELISTED
Vitamin Shoppe Inc.
VSI
| $936K | ﹤0.01% |
+80,301
| New | +$1.18M |
|
|
RDC
2579
DELISTED
Rowan Companies Plc
RDC
| $936K | ﹤0.01% |
+91,400
| New | +$1.2M |
|
2580
Assurant
AIZ
$13.9B
| $933K | ﹤0.01% |
+9,000
| New | +$896K |
|
2581
Innodata
INOD
$2.03B
| $933K | ﹤0.01% |
533,200
+12,000
| +2% | +$21.5K |
|
|
GTLS
2582
DELISTED
Chart Industries
GTLS
| $931K | ﹤0.01% |
26,800
+8,700
| +48% | +$303K |
|
|
LTS
2583
DELISTED
Ladenburg Thalmann Financial Services Inc
LTS
| $929K | ﹤0.01% |
380,600
-27,700
| -7% | -$67K |
|
2584
MIND Technology
MIND
$42.6M
| $927K | ﹤0.01% |
23,890
+1,871
| +8% | +$82.1K |
|
|
ALR
2585
DELISTED
AlerisLife Inc
ALR
| $927K | ﹤0.01% |
61,814
+5,240
| +9% | +$94.8K |
|
|
CEQP
2586
DELISTED
Crestwood Equity Partners LP
CEQP
| $925K | ﹤0.01% |
39,382
+1,700
| +5% | +$41.1K |
|
|
TRT
2587
Trio-Tech International
TRT
$118M
| $922K | ﹤0.01% |
370,400
+85,400
| +30% | +$201K |
|
2588
Marcus & Millichap
MMI
$1.18B
| $920K | ﹤0.01% |
34,900
-19,300
| -36% | -$485K |
|
2589
Sypris Solutions
SYPR
$46.8M
| $920K | ﹤0.01% |
557,688
+33,988
| +6% | +$45.7K |
|
2590
Turning Point Brands
TPB
$1.73B
| $919K | ﹤0.01% |
59,920
+17,720
| +42% | +$283K |
|
|
LITB
2591
LightInTheBox
LITB
$56.7M
| $918K | ﹤0.01% |
52,783
+2,350
| +5% | +$36.7K |
|
|
SSNI
2592
DELISTED
Silver Spring Networks, Inc.
SSNI
| $916K | ﹤0.01% |
81,199
-10,601
| -12% | -$115K |
|
|
CVO
2593
DELISTED
Cenevo, Inc.
CVO
| $915K | ﹤0.01% |
150,247
+8,300
| +6% | +$43.3K |
|
2594
Kinsale Capital Group
KNSL
$8.59B
| $914K | ﹤0.01% |
24,500
+3,100
| +14% | +$109K |
|
|
IEC
2595
DELISTED
IEC Electronics Corp.
IEC
| $910K | ﹤0.01% |
252,700
-9,900
| -4% | -$36.7K |
|
2596
KB Financial Group
KB
$41.4B
| $904K | ﹤0.01% |
17,900
-112,800
| -86% | -$5.25M |
|
|
LOAN
2597
Manhattan Bridge Capital
LOAN
$47.2M
| $898K | ﹤0.01% |
151,000
+300
| +0.2% | +$1.61K |
|
|
CCM
2598
Concord Medical Services
CCM
$20.8M
| $896K | ﹤0.01% |
23,900
+3,990
| +20% | +$162K |
|
2599
Fossil Group
FOSL
$330M
| $889K | ﹤0.01% |
85,900
-335,100
| -80% | -$4.53M |
|
2600
Scully Royalty
SRL
$90.9M
| $886K | ﹤0.01% |
99,523
-680
| -0.7% | -$5.5K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.